Regeneron Pharmaceuticals has taken new steps to expand its work in obesity treatment by licensing a weight loss drug and sharing study results for two drugs aimed at preserving muscle mass. These efforts are part of the company’s broader plan to address health problems related to obesity.
In separate news, two biotech firms focused on neuroscience, Atai Life Sciences and Alto Neuroscience, announced new partnerships. Their goal is to advance brain-related treatments and develop therapies for mental health conditions.
Additionally, Bluebird Bio completed its transition from a publicly traded company to a private one. This change marks a major shift in how the company operates.
Related Topics:
Flow Athletic Cofounder Ben Lucas Lost 25kg By Diet
Woman Unrecognisable After Six Stone Weight Loss
Common Diet Brits Use To Lose Weight May Lead To Depression Study Finds